Skip to content
OpenTrain AIFor AI Companies

HFEPX · Eval paper review

From Benchmarks to the Bench: Preference, Correspondence and Selectivity in Bidirectional Drug-Target Screening

Jiangjie Qiu, Chengrui Xu, Xiaonan Wang

Published

Nov 21, 2026

Citations

0

Trust level

Low

Usefulness score

40/100 (Low)

Extraction confidence

45% (Low)

Derived from extracted protocol signals and abstract evidence.

Rater population

Not reported

Signals refreshed

Nov 21, 2026

Should you rely on this paper?

This paper is adjacent to HFEPX scope and is best used for background context, not as a primary protocol reference.

Use this as background context only. Do not make protocol decisions from this page alone.

Best use

Background context only

Use if you need

Background context only.

What to verify

Read the full paper before copying any benchmark, metric, or protocol choices.

Main weakness

The available metadata is too thin to trust this as a primary source.

Human feedback signal
Detected
From extracted signals
Evaluation signal
Weak or implicit
Validate from full paper
Usefulness for eval research
40/100
Adjacent candidate

Treat as adjacent context, not a core eval-method reference.

Abstract

Identifying active molecules for known targets and potential targets for existing drugs is central to drug discovery and repurposing. Drug-target interaction (DTI) models can rank vast numbers of drug-target pairs, but limited experimental capacity restricts testing to a small number of candidates. We compared the bidirectional recommendations of 13 released systems across 711 molecular structures of FDA-approved drugs and 614 human proteins. For the same target or drug, pairs of models produced completely disjoint Top-10 molecule and protein lists in 77.8% and 70.1% of comparisons, respectively. Even where recommendations overlapped, agreement between some systems largely reflected recurring preferences for the same candidates. Published inhibition measurements for 79 molecules and 65 kinases revealed that some systems enriched active candidates, yet their hit yields changed little when recommendations were matched to different drugs or targets, whereas other systems lost substantially more hits. Some of the former systems also rarely ranked both molecules and kinases correctly when two drugs favoured different kinases. We further retrained the same architecture on the same data, with the training objective fixed and random seeds varied. Despite similar test performance, mean pairwise Top-10 overlap on a separate screening catalogue was about two candidates. Our study moves DTI model evaluation beyond benchmark performance to assess whether model predictions can guide meaningful experimental decisions in drug discovery and target identification.

What we could verify

These are the protocol signals we could actually recover from the available paper metadata. Use them to decide whether this paper is worth deeper reading.

Human Feedback Types

partial

Pairwise Preference

Directly usable for protocol triage.

"Identifying active molecules for known targets and potential targets for existing drugs is central to drug discovery and repurposing."

Evaluation Modes

missing

None explicit

Validate eval design from full paper text.

"Identifying active molecules for known targets and potential targets for existing drugs is central to drug discovery and repurposing."

Quality Controls

missing

Not reported

No explicit QC controls found.

"Identifying active molecules for known targets and potential targets for existing drugs is central to drug discovery and repurposing."

Benchmarks / Datasets

missing

Not extracted

No benchmark anchors detected.

"Identifying active molecules for known targets and potential targets for existing drugs is central to drug discovery and repurposing."

Reported Metrics

missing

Not extracted

No metric anchors detected.

"Identifying active molecules for known targets and potential targets for existing drugs is central to drug discovery and repurposing."

Benchmarks and datasets

No benchmark or dataset names were extracted from the available abstract.

Reported metrics

No metric terms were extracted from the available abstract.

Human feedback details
Uses human feedback
Yes
Feedback types
Pairwise Preference
Rater population
Not reported
Unit of annotation
Pairwise (inferred)
Expertise required
General
Evaluation details
Evaluation modes
None
Agentic eval
None
Quality controls
Not reported
Evidence quality
Low
Use this page as
Background context only

Research brief

Metadata summary

Identifying active molecules for known targets and potential targets for existing drugs is central to drug discovery and repurposing.

Based on abstract + metadata only. Check the source paper before making high-confidence protocol decisions.

Key takeaways

  • Identifying active molecules for known targets and potential targets for existing drugs is central to drug discovery and repurposing.
  • Drug-target interaction (DTI) models can rank vast numbers of drug-target pairs, but limited experimental capacity restricts testing to a small number of candidates.
  • We compared the bidirectional recommendations of 13 released systems across 711 molecular structures of FDA-approved drugs and 614 human proteins.

Researcher actions

  • Compare this paper against nearby papers in the same arXiv category before using it for protocol decisions.
  • Check the full text for explicit evaluation design choices (raters, protocol, and metrics).
  • Use related-paper links to find stronger protocol-specific references.

Caveats

  • Generated from abstract + metadata only; no PDF parsing.
  • Signals below are heuristic and may miss details reported outside the abstract.

Contribution summary

  • Identifying active molecules for known targets and potential targets for existing drugs is central to drug discovery and repurposing.
  • Drug-target interaction (DTI) models can rank vast numbers of drug-target pairs, but limited experimental capacity restricts testing to a small number of candidates.

Why it matters for eval

  • Our study moves DTI model evaluation beyond benchmark performance to assess whether model predictions can guide meaningful experimental decisions in drug discovery and target identification.

Researcher checklist

  • Human feedback protocol is explicit

    Detected: Pairwise Preference

  • Evaluation mode is explicit

    No clear evaluation mode extracted.

  • Quality control reporting appears

    No calibration/adjudication/IAA control explicitly detected.

  • Benchmark or dataset anchors are present

    No benchmark/dataset anchor extracted from abstract.

  • Metric reporting is present

    No metric terms extracted.